Retina/Vitreous News

The FDA granted rare pediatric disease designation to ATSN-201, a gene therapy candidate for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

Vitreoretinal surgery fellows tend to become faster at peeling over the course of their fellowship, according to a study presented at the American Society of Retina Specialists annual meeting.

In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses 36-month real-world data on the Yutiq implant for the treatment of chronic noninfectious uveitis.

Healio spoke with Bradley Dougherty, OD, PhD, associate professor at The Ohio State University College of Optometry, about how socioeconomic factors can affect the diagnosis, treatment and outcomes of age-related macular degeneration.

A questionnaire found that the majority of retina fellows planned to go into a retina-only private practice.

Eclipse Life Sciences has enrolled and dosed the first patient in the BETTIS-1 phase 2 clinical trial investigating the EC-104 implant for the treatment of diabetic macular edema, according to a press release.

Patient education materials related to age-related macular degeneration treatment are often written at inappropriate reading levels and lack accountability, according to a presentation at the American Society of Retina Specialists meeting.

An AI program accurately identified posterior vitreous opacities in patients with posterior vitreous detachments, which may improve screening for retinal tears, according to a study.

The progression of myopia among school-aged children in China appeared to primarily affect changes in inner retinal thickness over the course of 1 year, according to research.

The FDA approved the Enzeevu 2 mg vial kit and prefilled syringe for intravitreal injection for the treatment of neovascular age-related macular degeneration, according to a press release from Sandoz.